APO RESEARCH · REPORT
Infantile Spasms Therapeutics
An infantile spasm (IS), also known as West Syndrome, is a specific type of seizure seen in an epilepsy syndrome of infancy and childhood. West Syndrome is characterized by infantile spasms, developmental regression, and a specific pattern on electroencephalography (EEG) testing called hypsarrhythmia (chaotic brain waves). The onset of infantile spasms is usually in the first year of life, typically between 4-8 months. The seizures primarily consist of a sudden bending forward of the body with stiffening of the arms and legs; some children arch their backs as they extend their arms and legs. The condition is usually observed in 2% of childhood epilepsies and 25% of epilepsies that start in the first year of life.
Product & engineering
Understand the product.
An infantile spasm (IS), also known as West Syndrome, is a specific type of seizure seen in an epilepsy syndrome of infancy and childhood. West Syndrome is characterized by infantile spasms, developmental regression, and a specific pattern on electroencephalography (EEG) testing called hypsarrhythmia (chaotic brain waves). The onset of infantile spasms is usually in the first year of life, typically between 4-8 months. The seizures primarily consist of a sudden bending forward of the body with stiffening of the arms and legs; some children arch their backs as they extend their arms and legs. The condition is usually observed in 2% of childhood epilepsies and 25% of epilepsies that start in the first year of life.
Selected research
Industry Research
Infantile Spasms Therapeutics Industry Research Report 2026
Market perspective
An infantile spasm (IS), also known as West Syndrome, is a specific type of seizure seen in an epilepsy syndrome of infancy and childhood. West Syndrome is characterized by infantile spasms, developmental regression, and a specific pattern on electroencephalography (EEG) testing called hypsarrhythmia (chaotic brain waves). The onset of infantile spasms is usually in the first year of life, typically between 4-8 months. The seizures primarily consist of a sudden bending forward of the body with stiffening of the arms and legs; some children arch their backs as they extend their arms and legs. The condition is usually observed in 2% of childhood epilepsies and 25% of epilepsies that start in the first year of life.
Global Infantile Spasms Therapeutics key players include Mallinckrodt, H. Lundbeck, etc. Global top two manufacturers hold a share over 60%.
In terms of product, Oral is the largest segment, with a share obout 55%. And in terms of application, the largest application is Hospital, followed by Clinic, etc.
Read the full market overview
Report Scope
This report quantifies the global Infantile Spasms Therapeutics market in terms of revenue (US$ million) and, where applicable, service volume (Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Infantile Spasms Therapeutics.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Infantile Spasms Therapeutics Market by Company
Mallinckrodt
H. Lundbeck
Insys Therapeutics
Orphelia Pharma
Valerion Therapeutics
Catalyst Pharmaceuticals
Anavex Life Sciences
Retrophin
GW Pharmaceuticals
Infantile Spasms Therapeutics Segment by Type
Oral
Injection
Infantile Spasms Therapeutics Segment by Application
Hospital
Clinic
Other
Infantile Spasms Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Infantile Spasms Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Infantile Spasms Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Infantile Spasms Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Infantile Spasms Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oral
- Injection
Applications
- Hospital
- Clinic
- Other
Companies covered
- Mallinckrodt
- H. Lundbeck
- Insys Therapeutics
- Orphelia Pharma
- Valerion Therapeutics
- Catalyst Pharmaceuticals
- Anavex Life Sciences
- Retrophin
- GW Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Infantile Spasms Therapeutics by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Oral
- 2.2.3 Injection
- 2.3 Infantile Spasms Therapeutics by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Clinic
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 Infantile Spasms Therapeutics Breakdown Data by Type
- 3.1 Global Infantile Spasms Therapeutics Historic Market Size by Type (2021-2026)
- 3.2 Global Infantile Spasms Therapeutics Forecasted Market Size by Type (2027-2032)
4 Infantile Spasms Therapeutics Breakdown Data by Application
- 4.1 Global Infantile Spasms Therapeutics Historic Market Size by Application (2021-2026)
- 4.2 Global Infantile Spasms Therapeutics Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Infantile Spasms Therapeutics Market Perspective (2021-2032)
- 5.2 Global Infantile Spasms Therapeutics Growth Trends by Region
- 5.2.1 Global Infantile Spasms Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Infantile Spasms Therapeutics Historic Market Size by Region (2021-2026)
- 5.2.3 Infantile Spasms Therapeutics Forecasted Market Size by Region (2027-2032)
- 5.3 Infantile Spasms Therapeutics Market Dynamics
- 5.3.1 Infantile Spasms Therapeutics Industry Trends
- 5.3.2 Infantile Spasms Therapeutics Market Drivers
- 5.3.3 Infantile Spasms Therapeutics Market Challenges
- 5.3.4 Infantile Spasms Therapeutics Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Infantile Spasms Therapeutics Players by Revenue
- 6.1.1 Global Top Infantile Spasms Therapeutics Players by Revenue (2021-2026)
- 6.1.2 Global Infantile Spasms Therapeutics Revenue Market Share by Players (2021-2026)
- 6.2 Global Infantile Spasms Therapeutics Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Infantile Spasms Therapeutics Head Office and Area Served
- 6.4 Global Infantile Spasms Therapeutics Players, Product Type & Application
- 6.5 Global Infantile Spasms Therapeutics Manufacturers Established Date
- 6.6 Global Infantile Spasms Therapeutics Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Infantile Spasms Therapeutics Market Size (2021-2032)
- 7.2 North America Infantile Spasms Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Infantile Spasms Therapeutics Market Size by Country (2021-2026)
- 7.4 North America Infantile Spasms Therapeutics Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Infantile Spasms Therapeutics Market Size (2021-2032)
- 8.2 Europe Infantile Spasms Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Infantile Spasms Therapeutics Market Size by Country (2021-2026)
- 8.4 Europe Infantile Spasms Therapeutics Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Infantile Spasms Therapeutics Market Size (2021-2032)
- 9.2 Asia-Pacific Infantile Spasms Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Infantile Spasms Therapeutics Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Infantile Spasms Therapeutics Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Infantile Spasms Therapeutics Market Size (2021-2032)
- 10.2 South America Infantile Spasms Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Infantile Spasms Therapeutics Market Size by Country (2021-2026)
- 10.4 South America Infantile Spasms Therapeutics Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Infantile Spasms Therapeutics Market Size (2021-2032)
- 11.2 Middle East & Africa Infantile Spasms Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Infantile Spasms Therapeutics Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Infantile Spasms Therapeutics Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Mallinckrodt
- 12.1.1 Mallinckrodt Company Information
- 12.1.2 Mallinckrodt Business Overview
- 12.1.3 Mallinckrodt Revenue in Infantile Spasms Therapeutics Business (2021-2026)
- 12.1.4 Mallinckrodt Infantile Spasms Therapeutics Product Portfolio
- 12.1.5 Mallinckrodt Recent Developments
- 12.2 H. Lundbeck
- 12.2.1 H. Lundbeck Company Information
- 12.2.2 H. Lundbeck Business Overview
- 12.2.3 H. Lundbeck Revenue in Infantile Spasms Therapeutics Business (2021-2026)
- 12.2.4 H. Lundbeck Infantile Spasms Therapeutics Product Portfolio
- 12.2.5 H. Lundbeck Recent Developments
- 12.3 Insys Therapeutics
- 12.3.1 Insys Therapeutics Company Information
- 12.3.2 Insys Therapeutics Business Overview
- 12.3.3 Insys Therapeutics Revenue in Infantile Spasms Therapeutics Business (2021-2026)
- 12.3.4 Insys Therapeutics Infantile Spasms Therapeutics Product Portfolio
- 12.3.5 Insys Therapeutics Recent Developments
- 12.4 Orphelia Pharma
- 12.4.1 Orphelia Pharma Company Information
- 12.4.2 Orphelia Pharma Business Overview
- 12.4.3 Orphelia Pharma Revenue in Infantile Spasms Therapeutics Business (2021-2026)
- 12.4.4 Orphelia Pharma Infantile Spasms Therapeutics Product Portfolio
- 12.4.5 Orphelia Pharma Recent Developments
- 12.5 Valerion Therapeutics
- 12.5.1 Valerion Therapeutics Company Information
- 12.5.2 Valerion Therapeutics Business Overview
- 12.5.3 Valerion Therapeutics Revenue in Infantile Spasms Therapeutics Business (2021-2026)
- 12.5.4 Valerion Therapeutics Infantile Spasms Therapeutics Product Portfolio
- 12.5.5 Valerion Therapeutics Recent Developments
- 12.6 Catalyst Pharmaceuticals
- 12.6.1 Catalyst Pharmaceuticals Company Information
- 12.6.2 Catalyst Pharmaceuticals Business Overview
- 12.6.3 Catalyst Pharmaceuticals Revenue in Infantile Spasms Therapeutics Business (2021-2026)
- 12.6.4 Catalyst Pharmaceuticals Infantile Spasms Therapeutics Product Portfolio
- 12.6.5 Catalyst Pharmaceuticals Recent Developments
- 12.7 Anavex Life Sciences
- 12.7.1 Anavex Life Sciences Company Information
- 12.7.2 Anavex Life Sciences Business Overview
- 12.7.3 Anavex Life Sciences Revenue in Infantile Spasms Therapeutics Business (2021-2026)
- 12.7.4 Anavex Life Sciences Infantile Spasms Therapeutics Product Portfolio
- 12.7.5 Anavex Life Sciences Recent Developments
- 12.8 Retrophin
- 12.8.1 Retrophin Company Information
- 12.8.2 Retrophin Business Overview
- 12.8.3 Retrophin Revenue in Infantile Spasms Therapeutics Business (2021-2026)
- 12.8.4 Retrophin Infantile Spasms Therapeutics Product Portfolio
- 12.8.5 Retrophin Recent Developments
- 12.9 GW Pharmaceuticals
- 12.9.1 GW Pharmaceuticals Company Information
- 12.9.2 GW Pharmaceuticals Business Overview
- 12.9.3 GW Pharmaceuticals Revenue in Infantile Spasms Therapeutics Business (2021-2026)
- 12.9.4 GW Pharmaceuticals Infantile Spasms Therapeutics Product Portfolio
- 12.9.5 GW Pharmaceuticals Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst